Search

everythinglearnresearchcommunity

for

Search:↓

Compounded topical preparations should be used with caution for severe psoriasis and generally come after systemic treatments.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

The robotic system for hair restoration surgery works well, giving similar results to manual techniques after 9 months.

Spironolactone safely and effectively treats hair loss in female scarring alopecia patients.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

European guidelines recommend regular eye and ear exams, skin care, vitamin D supplements, and cautious use of medications for managing congenital ichthyoses.

The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.

Some growth factors, while important for normal body functions, can cause diseases when not regulated properly.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.

Shrinking of oil glands in the skin is a key sign of hair loss linked to TNF inhibitor drugs and may improve if the treatment is stopped.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.